While these data suggest a potential beneficial role for mTOR inhibitors, it is important to mention that in many cancer settings the use of some inhibitors of the PI3Ks-dependent pathways has unfortunately led to the discovery of compensatory mechanisms that reduce their therapeutic efficiency [146,147]. This evidence concerns the gene MTOR and cancer.